| scholarly article | Q13442814 |
| P50 | author | Munir Pirmohamed | Q20127995 |
| P2093 | author name string | B Kevin Park | |
| P2860 | cites work | Adverse drug reactions | Q24524192 |
| COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression | Q24536398 | ||
| Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 | ||
| Genetic variations in HLA-B region and hypersensitivity reactions to abacavir | Q28214097 | ||
| Timing of new black box warnings and withdrawals for prescription medications | Q28216033 | ||
| Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies | Q29616299 | ||
| Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study | Q29620671 | ||
| Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention | Q30661684 | ||
| Pharmacoepidemiological research at the Medicines Monitoring Unit, Scotland: data protection and confidentiality | Q30690045 | ||
| The safety of newly approved medicines: do recent market removals mean there is a problem? | Q33635589 | ||
| Antithrombotic therapy for atrial fibrillation | Q33812662 | ||
| TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. | Q33941873 | ||
| Allergic reactions to drugs: involvement of T cells | Q34036255 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy | Q34153600 | ||
| Oral anticoagulation and risk of death: a medical record linkage study | Q34210279 | ||
| Genetic susceptibility to adverse drug reactions | Q34275394 | ||
| Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions | Q34323071 | ||
| Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy | Q34346405 | ||
| Science, medicine and clinical pharmacology. The Lilly Lecture 1994. | Q34347099 | ||
| Idiosyncratic drug reactions: a mechanistic evaluation of risk factors | Q34403403 | ||
| Renal failure associated with the use of celecoxib and rofecoxib | Q34716897 | ||
| Peptic-ulcer disease | Q34921684 | ||
| New active substances authorized in the United Kingdom between 1972 and 1994. | Q35802118 | ||
| A clinical pharmacologist's view of drug toxicity | Q36093696 | ||
| Methyldopa-induced autoantibodies against red blood cells | Q39647483 | ||
| Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons | Q40618049 | ||
| Demand for warfarin anticoagulation monitoring in Tayside, Scotland. | Q40901128 | ||
| Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury | Q41757692 | ||
| Reporting of adverse drug reactions by hospital pharmacists: pilot scheme | Q42027646 | ||
| Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. | Q42056657 | ||
| Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database | Q43921096 | ||
| Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites | Q44184007 | ||
| Selective COX-2 inhibitors: are they safe for the stomach? | Q47899828 | ||
| Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994. | Q48509535 | ||
| 150 years of pharmacovigilance. | Q53574640 | ||
| The Role of Active Metabolites in Drug Toxicity | Q56474940 | ||
| Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study | Q57302798 | ||
| Reporting of adverse drug reactions: practice in the UK | Q57302805 | ||
| Role of Drug Disposition in Drug Hypersensitivity: A Chemical, Molecular, and Clinical Perspective | Q57302806 | ||
| Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity | Q57302832 | ||
| Adverse reactions to TNF-α inhibitors in rheumatoid arthritis | Q57415315 | ||
| Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications | Q63241969 | ||
| Methyldopa and haemolytic anaemia | Q70061795 | ||
| Incidence of a positive direct coombs test in patients on alpha-methyldopa | Q70066192 | ||
| Positive direct Coombs tests and antinuclear factor in patients treated with methyldopa | Q70079102 | ||
| The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics | Q71064706 | ||
| Protein-reactive metabolites of carbamazepine in mouse liver microsomes | Q71302767 | ||
| Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s) | Q71520161 | ||
| Anticonvulsant hypersensitivity syndrome | Q71558221 | ||
| Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 | Q71996232 | ||
| The MedWatch Program | Q73234873 | ||
| Adverse drug reactions in hospitalized patients: A critique of a meta-analysis | Q73264797 | ||
| Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use | Q73487778 | ||
| Antiretroviral therapy and the lipodystrophy syndrome | Q74061740 | ||
| Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs | Q74509832 | ||
| The UK General Practice Research Database | Q77357717 | ||
| Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs | Q77499075 | ||
| Drug-induced systemic lupus erythematosus associated with etanercept therapy | Q77696979 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 486-492 | |
| P577 | publication date | 2003-05-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Adverse drug reactions: back to the future | |
| P478 | volume | 55 |
| Q59813409 | Clinical factors predicting drug-induced liver injury due to flucloxacillin |
| Q46975372 | Clinical perspectives in drug safety and adverse drug reactions |
| Q35778961 | Clinical pharmacology: special safety considerations in drug development and pharmacovigilance |
| Q35632119 | Drug allergy |
| Q57111849 | Drug allergy |
| Q75319379 | Genetic screening for susceptibility to infection in the NICU setting |
| Q46696759 | Incidence and cost estimate of treating pediatric adverse drug reactions in Lagos, Nigeria |
| Q28078315 | Non-psychotropic medication and risk of suicide or attempted suicide: a systematic review |
| Q51146167 | Ten-year trends in hospital admissions for adverse drug reactions in England 1999-2009. |
| Q95357296 | The 10-D assessment and evidence-based medicine tool for authors and peer reviewers in clinical pharmacology |
| Q37638867 | The effects of distraction on symptoms during drug provocation test |
| Q42842878 | Topical promethazine side effects: our experience and review of the literature |
| Q34580615 | Using primary care prescribing databases for pharmacovigilance |
Search more.